Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02071901

Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This phase II trial studies how well eltrombopag olamine works in improving the recovery of platelet counts in older patients with acute myeloid leukemia undergoing induction (the first treatment given for a disease) chemotherapy. Platelet counts recover more slowly in older patients, leading to risk of complications and the delay of post-remission therapy. Eltrombopag olamine may cause the body to make platelets after chemotherapy.

Status: 
Recruiting
Study Date: 
Fri, 08/01/2014 to Sat, 10/01/2016
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: eltrombopag olamine Given PO Other Names: Promacta SB 497115 SB-497115 SB497115